Austria Flow Cytometry Market Would be Worth $27.7 Million, by 2020

Austria flow cytometry market report, published by Allied Market Research, forecasts that the Austria market was valued at $14.0 million in 2014, and is expected to reach $27.7 million by 2020, supported by a CAGR of 12.3% during the forecast period 2015- 2020. Academics and clinical research segments collectively accounted for about two-third of the market in 2014. However, industrial application segment is expected to exhibit an impressive growth over the forecast period.

High diagnosis rates, increasing count of research activities, growing adoption in diagnosis of solid tumors and hematological malignancies, rising incidences of cancer, and high rate of HIV tests per capita in Austria would continue to bolster flow cytometry market in Austria. Several funding agencies and societies are investing in flow cytometry related R&D activities at the academic and institutional level; thereby, driving the Austria flow cytometry market growth. Emerging applications across novel fields of research, such as plant science and production, marine biology, genomics, proteome analysis, among others, would further boost the market growth. However, factors such as high cost associated with the instruments and limited technical know-how would impede the market growth.

Key findings of Austria Flow Cytometry Market:

• Instruments segment accounted for more than half of the Austria flow cytometry market in 2014; whereas, the reagents segment is projected to exhibit highest CAGR of 14.1%, during 20152020.
• Cell-based technology segment accounted for four-fifths of the Austria flow cytometry market in 2014.
• Within the clinical application, sorting/screening segment is projected as the fastest growing segment, registering a CAGR of 12.6% during the analysis period.
• Within industrial application, hematological malignancies segment is expected to be one of the most lucrative segments throughout the forecast period.
• Within end-users, commercial organizations segment would continue to maintain its dominant position, contributing around 36% of the market revenue, by 2020.

Product launch is the key developmental strategy adopted by the leading players in the market. In addition, the market players have also adopted strategies, such as acquisitions and collaborations, to bolster their market position. The key companies profiled in the report include Danaher Corporation, Becton, Dickenson and Co., Merck Millipore, Bio-Rad Laboratories, Inc., and Agilent Technologies, Inc.